罗格列酮对2型糖尿病合并不稳定性心绞痛患者血清MMP-9及IL-18的影响

Effects of rosiglitazone on expression of serum MMP-9 and IL-18 in patients with type 2 diabetes mellitus and unstable angina pectoris

目的观察罗格列酮对2型糖尿病合并不稳定性心绞痛患者血清基质金属蛋白酶-9(MMP-9)及白细胞介素-18(IL-18)的影响。方法 82例2型糖尿病合并不稳定性心绞痛患者,随机分为罗格列酮组(n=41)和常规治疗组(n=41)。观察两组治疗前后空腹血糖、血脂及血清MMP-9I、L-18的差别。结果治疗前两组患者空腹血糖、血脂及血清MMP-9I、L-18的水平无显著差异(P>0.05);治疗4个月后,两组患者空腹血糖、血脂无显著差异,血清MMP-9及IL-18较治疗前均下降(P<0.01),罗格列酮组较常规治疗组下降明显,两组间差异显著(P<0.05)。结论罗格列酮能减少糖尿病合并不稳定心绞痛患者炎症介质的分泌,可能具有改善动脉粥样硬化的作用。

Objective To explore the effects of rosiglitazone on the expression of serum matrix metalloproteinase-9（MMP-9）and interleukin-18（IL-18）in patients with type 2 diabetes mellitus and unstable angina pectoris.Methods 82 patients with type 2 diabetes mellitus and unstable angina pectoris were randomly divided into rosiglitazone group（n=41）and routine treatment group（n=41）.Before and after the treatment,the differences in fasting plasma glucose（FPG）,blood fat,serum MMP-9 and IL-18 were detected.Results Before the treatment,the FPG,blood fat,serum MMP-9 and IL-18 between the two groups showed not any significant differences（P0.05）.After the treatment for 4 months,there were not significant differences in the FPG and the blood fat between the two groups.Compared with the pretherapy,the serum MMP-9 and IL-18 of both groups decreased after the treatment and the decrease in the rosiglitazone group was more obvious than that of the other group（P0.05）.Conclusion Rosiglitazone can diminish the secretion of inflammatory mediators in patients with type 2 diabetes mellitus and unstable angina pectoris,and consequently might ameliorate atherosclerosis in such patients.